ShutterstockTwo studies that compared intracellular levels of the drugs used in PrEP found that levels of tenofovir in cells were seven times higher when the newer version of the tenofovir prodrug, tenofovir alafenamide (TAF), was used, than when the older version, tenofovir disoproxil fumarate (TDF), was used.
TDF has been used for HIV treatment for 20 years and is a component of most PrEP tablets, including Truvada. Tablets containing TAF have only been marketed in the last five years and include Descovy, which has been licensed for use as PrEP in the United States, Canada, Australia and Taiwan, but not elsewhere.
Read the full story at Aidsmap.
Source : Aidsmap
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.